Innovations That Address Treatment Burden in nAMD and DME

Author(s)/Faculty: John W. Kitchens, MD; Rishi P. Singh, MD
Release Date: 7/8/2022Expiration Date: 7/7/2023
Credit Type: CMENumber of Credits: 0.75
Content Type: LectureProvider:
Pinnacle clinical studies evaluating anti-vascular endothelial growth factor (VEGF) therapies in the management of diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD) have demonstrated significant visual and anatomical improvements. However, real-world outcomes do not always align with these pinnacle studies, in part due to the treatment burden and lack of patient adherence. Corticosteroid therapy is also an effective option for DME but is often not effectively integrated into management protocols. There is continued refinement of treatment protocols with current therapies and inclusion of novel delivery systems, gene therapy, and integration of agents with unique mechanisms of action into practice, with the intention of addressing the treatment burden through extending the interval between dosing schedules. In this continuing medical education activity, experts in the field review injectable therapies that lengthen dosing intervals in patients with nAMD and DME as well as discuss new and emerging surgical therapies that can reduce the need for frequent anti-VEGF injections in these patients.